argenx NV ADR (ARGX)vsCoherus BioSciences Inc (CHRS)
ARGX
argenx NV ADR
$891.32
+5.82%
HEALTHCARE · Cap: $55.09B
CHRS
Coherus BioSciences Inc
$1.45
-7.94%
HEALTHCARE · Cap: $227.52M
Smart Verdict
WallStSmart Research — data-driven comparison
argenx NV ADR generates 10016% more annual revenue ($4.74B vs $46.88M). CHRS leads profitability with a 397.3% profit margin vs 31.4%. ARGX earns a higher WallStSmart Score of 73/100 (B).
ARGX
Strong Buy73
out of 100
Grade: B
CHRS
Hold47
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+62.4%
Fair Value
$2217.64
Current Price
$891.32
$1326.32 discount
Intrinsic value data unavailable for CHRS.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Keeps 31 of every $100 in revenue as profit
Strong operational efficiency at 30.0%
Revenue surging 62.6% year-over-year
Earnings expanding 114.0% YoY
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Keeps 397 of every $100 in revenue as profit
Revenue surging 62.0% year-over-year
Reasonable price relative to book value
Areas to Watch
Premium valuation, high expectations priced in
Weak financial health signals
Trading at 188.4x book value
Smaller company, higher risk/reward
ROE of -192.9% — below average capital efficiency
Earnings declined 75.5%
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : ARGX
The strongest argument for ARGX centers on Profit Margin, Operating Margin, Revenue Growth. Profitability is solid with margins at 31.4% and operating margin at 30.0%. Revenue growth of 62.6% demonstrates continued momentum.
Bull Case : CHRS
The strongest argument for CHRS centers on Profit Margin, Revenue Growth, Price/Book. Profitability is solid with margins at 397.3% and operating margin at -293.7%. Revenue growth of 62.0% demonstrates continued momentum.
Bear Case : ARGX
The primary concerns for ARGX are P/E Ratio, Piotroski F-Score, Price/Book.
Bear Case : CHRS
The primary concerns for CHRS are Market Cap, Return on Equity, EPS Growth.
Key Dynamics to Monitor
CHRS carries more volatility with a beta of 0.96 — expect wider price swings.
ARGX is growing revenue faster at 62.6% — sustainability is the question.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ARGX scores higher overall (73/100 vs 47/100), backed by strong 31.4% margins and 62.6% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
argenx NV ADR
HEALTHCARE · BIOTECHNOLOGY · USA
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
Coherus BioSciences Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilars and immuno-oncology market primarily in the United States. The company is headquartered in Redwood City, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?